Charles Schwab Investment Management Inc. Has $195,000 Position in Lexeo Therapeutics, Inc. $LXEO

Charles Schwab Investment Management Inc. lessened its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 12.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 56,174 shares of the company’s stock after selling 7,700 shares during the period. Charles Schwab Investment Management Inc. owned about 0.17% of Lexeo Therapeutics worth $195,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Millennium Management LLC lifted its position in Lexeo Therapeutics by 282.5% during the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock worth $934,000 after buying an additional 104,837 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Lexeo Therapeutics by 523.1% during the 4th quarter. BNP Paribas Financial Markets now owns 34,527 shares of the company’s stock worth $227,000 after buying an additional 28,986 shares in the last quarter. Wellington Management Group LLP lifted its position in Lexeo Therapeutics by 48.3% during the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after buying an additional 25,089 shares in the last quarter. Barclays PLC lifted its position in Lexeo Therapeutics by 9.9% during the 4th quarter. Barclays PLC now owns 55,161 shares of the company’s stock worth $363,000 after buying an additional 4,951 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Lexeo Therapeutics by 172.8% during the 4th quarter. Deutsche Bank AG now owns 13,226 shares of the company’s stock worth $87,000 after buying an additional 8,378 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Shares of NASDAQ:LXEO opened at $4.97 on Friday. The company has a market capitalization of $268.38 million, a price-to-earnings ratio of -1.52 and a beta of 1.36. The firm’s 50 day simple moving average is $4.51 and its 200 day simple moving average is $3.68. Lexeo Therapeutics, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $11.72.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. Equities research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on LXEO shares. JPMorgan Chase & Co. reduced their price target on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, May 30th. HC Wainwright reduced their price target on shares of Lexeo Therapeutics from $15.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Chardan Capital reduced their price target on shares of Lexeo Therapeutics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Finally, Oppenheimer initiated coverage on shares of Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $15.33.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.